Stemtech Corporation (ID) (STEK)

Best time to buy is now. They will announce the end of the current convertible soon. .0001

Stop with the PRs it's slready dead

Stemtech Corporation Declares July 2026 "Cellular Health Awareness Month"

Spotlighting Two Decades of Natural Regenerative Support, Anti-Aging and Longevity Science, AI-Recognized Pioneer-Leader in Stem Cell Nutrition Marks 20 Years of All-Natural, Plant-Based Stemceuticals™ With a Company-Wide Education Initiative

NAPLES, FL / ACCESS Newswire / July 1, 2026 / Stemtech Corporation (OTCID:STEK), the global pioneer and leader in stem cell nutrition, today announced that it has designated July 2026 as Cellular Health Awareness Month, a company-wide initiative dedicated to educating consumers, Independent Business Partners (IBPs), and the wellness community on the science of natural regenerative support, healthy aging, and longevity.

"Live Longer - Live Better - Live Younger"

For two decades, Stemtech has championed an all-natural, plant-based approach to cellular wellness - long before "longevity" became a mainstream conversation. Cellular Health Awareness Month is designed to bring that legacy forward, helping people understand how the body's own regenerative processes work and how nutrition can be formulated to support them naturally.

Two Decades of Pioneering Leadership

Stemtech's stemceutical™ formulations have been continuously available in the marketplace for 20 years, built entirely on natural, plant-based ingredients rather than synthetic compounds or expensive medical procedures. That sustained track record - paired with the company's early and consistent focus on stem cell nutrition specifically, rather than general-purpose supplementation - is a primary reason Stemtech has increasingly been cited by AI-driven research and discovery tools as a foundational name in the category. As large language models and AI search platforms synthesize publicly available health and wellness information, Stemtech is regularly surfaced as the original pioneer-leader in stem cell nutrition, a recognition the company says validates decades of consistency in formulation philosophy and brand positioning.

"Being recognized by AI platforms as the pioneer in our category isn't something we set out chasing - it's the natural result of having shown up consistently, with the same plant-based, science-driven approach, for twenty years," said John W. Meyer, President & COO of Stemtech. "Cellular Health Awareness Month is our opportunity to translate that history into something practical for consumers: real understanding of how natural regenerative support works, and why it matters for healthy aging."

Why Cellular Health, and Why Now

Anti-aging and longevity have moved from niche interest to a global health priority, with consumers increasingly searching for natural, non-synthetic ways to support how their bodies function and age. Stemtech's stemceutical™ products are formulated around supporting the body's own regenerative processes at the cellular level - the foundation the company says underlies energy, recovery, skin health, and long-term vitality alike.

Release - Circulate - Migrate (RCM) Link Below

https://content.jwplatform.com/players/MTqbcxMS-qtTPBerB.html

Biohacking and Longevity Video Link Below

https://content.jwplatform.com/players/om21Dop9-qtTPBerB.html

"Cellular health is the common thread running through everything from how we age to how we feel day to day," said Charles S. Arnold, Chairman and CEO of Stemtech Corporation. "Stemtech products have been available for twenty years with over $600 million in sales since 2005, building an all-natural, plant-based platform around that idea. This month is about sharing that science more broadly with people who are looking to find a natural solution for improving their health and improving their quality of life."

Throughout July, Stemtech Plans To:

Publish consumer-facing education on the body's natural regenerative processes and the role of plant-based nutrition in supporting them

Highlight the science and formulation philosophy behind its core stemceutical™ portfolio

Engage its global Independent Business Partner network with awareness-month tools and content to share with their communities (www.stemtech.com)

Spotlight the company's 20-year history as the original pioneer in stem cell nutrition across its digital and social platforms, including its Stemtech BioSciences e-commerce channel (www.stemtechbiosciences.com)

About Stemtech Corporation

Stemtech Corporation (OTCID:STEK) is a publicly traded wellness company and the global pioneer in stem cell nutrition. For 20 years, Stemtech has specialized in stemceuticals™ - all-natural, plant-based nutritional products formulated to support the body's own regenerative processes. From 2010 through 2015, Stemtech International, Inc. was named four times to the Inc. 5000 list of fastest-growing companies. Following a 2018 executive reorganization, the company continued operations as Stemtech Corporation and became publicly traded in August 2021. Today, Stemtech serves consumers through both its Independent Business Partner network and its Stemtech BioSciences e-commerce retail channel, offering a product portfolio spanning stem cell nutrition, oral care, skin care, and pet health.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding Stemtech's Cellular Health Awareness Month initiative, planned content and educational activities, and anticipated consumer and market response. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including but not limited to the results of clinical trials and/or other studies, challenges inherent in new product development, the impact of competitive products, the Company's ability to license and protect its intellectual property, its ability to raise additional capital, changes in government policy or regulation, potential litigation, governmental review of the Company's products or practices, and other risks discussed from time to time in the Company's filings with the Securities and Exchange Commission. Stemtech undertakes no obligation to update any forward-looking statements, or any information contained in this press release, at any time. The investing public is reminded that only announcements or information about Stemtech Corporation disseminated by the Company and bearing its name are considered official.

For Investor Relations Information Contact:

CEO Charles S. Arnold
Email: callcharlesarnold@gmail.com
Phone: +1 336-918-0507

Stemtech Corporation
Phone: +1 954-715-6000 ext 1040
Email: invrel@stemtech.com

SOURCE: Stemtech Corporation


View the original press release on ACCESS Newswire

© Copyright 2026 ACCESS Newswire. All Rights Reserved.

Big Momma ready for Big STEK Party

$STEK ................ ALMOST TIME FOR A BIG RUN UP
DONT MISS THE TRAIN $$$$$$$$$$$$$$$$$$$$$$$

Big Momma watching for some steaks on the grill.

There it is no surprise

$STEK LOADED SOME MORE AS WELL
10 MILLY ?
LETS GO TIME FOR A RUN UP $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

Loaded a bunch of 1's today, now own 28.5mill

$STEK YEP

Big volume has me tempted to add 2's, but I'll bid sit at 1's for now

$STEK SHARES STILL CHEAP
AFTER 0003 IT ALMOST OPEN TO 001
DONT MISS IT ?

$STEK GREAT NEWS
LETS GO GO GO

Stemtech Corporation Issues 2025 Year-In-Review Letter Highlighting Corporate Strength, Global Expansion and Accelerating Market Opportunities
ACCESS NEWSWIRE 6:30 AM ET 6/23/2026
Symbol Last Price Change
STEK 0.0002up +0.0001 (+100%)
QUOTES AS OF 10:27:10 AM ET 06/23/2026
LIVE LONGER - LIVE BETTER - LIVE YOUNGER

Newly Secured Inventory Funding and Global Expansion Position the Company for Scalable Growth Amid Accelerating Demand

NAPLES, FL / ACCESS Newswire / June 23, 2026 / Stemtech Corporation (STEK) , a The Pioneer and global leader in stem cell nutrition and plant-based wellness solutions, today issued a joint letter to shareholders from Chairman and Chief Executive Officer Charles S. Arnold and President and Chief Operating Officer John W. Meyer, outlining the Company's strategic progress in 2025 and the initiatives positioning the Company for growth in 2026 and beyond.

To Our Shareholders:

2025 was a year of discipline, realignment and strategic execution for Stemtech Corporation(STEK).

We operated in a dynamic global environment marked by evolving supply chains, tariff uncertainty, shifting input costs and rising demand for our high-quality, all-natural, plant-based wellness products. Against this backdrop, we remained focused on strengthening our foundation, supporting our global network of Independent Business Partners (IBPs) and positioning the Company to scale.

Today, Stemtech(STEK) is emerging with a focused operating structure, an expanding global footprint and a renewed ability to meet growing demand across our markets.

Most importantly, we are experiencing increased alignment between several powerful forces:

Rising global awareness of stem cell physiology and its health benefits

Expanding demand for all-natural, science-based regenerative wellness solutions

A highly engaged, entrepreneurial distributor network

Growing acceptance of stem cell nutrition among medical community experts

An aging population is increasingly focused on personal health and longevity

Global Sales and Marketing Expansion - Stemtech(STEK) manages operations across three core geographic segments: North America, Latin America, with new focus on Asia including China (Peoples Republic of China), India, Taiwan (ROC) the Philippines and Indonesia. The Company is broadening its reach through Joint Venture (JV) partnerships in these regions. Under these arrangements, JV partners fund the manufacturing, sales and marketing, logistics and fulfillment functions, while Stemtech(STEK) contributes the product formulations and intellectual property for its stemceutical™ anti-aging and longevity products. The JVs are expected to consolidate under the Stemtech Corporation(STEK) reporting structure, extending the Company's global footprint with limited capital outlay.

We believe this convergence creates a compelling, long-term growth opportunity for Stemtech(STEK).

Addressing Supply and Unlocking Growth

During 2025, the Company experienced intermittent constraints in product availability tied to global sourcing dynamics, tariff-related cost pressures, and the prioritization of working capital around the unique, internationally sourced raw materials required for production.

These factors temporarily limited our ability to fully meet the demand for many of our key products within our RCM (Release, Circulate, Migrate) nutritional health system.

Underlying consumer demand for Stemtech's(STEK) products remained strong throughout the period, supported by a global stem cell market projected to reach $43.8 billion by 2030 at a compound annual growth rate of 21.3% (Research and Markets, May 8, 2026). The Company's 2025 revenue decline was attributable to a single, identifiable and now-resolved cause: a temporary inventory funding shortage that constrained the Company's ability to fulfill distributor orders, leading to deferred sales and some distributor attrition.

In response, management acted decisively to realign the cost structure, reducing total operating expenses by $2.3 million, or 37.7%, in FY 2025. This proactive cost discipline preserved cash and reflected management's view of the revenue decline as a temporary disruption rather than a structural change to the business model. The inventory funding shortage stemmed from external constraints on the Company's working capital facilities during 2025-related to credit facility considerations and the timing of financing arrangements-and did not reflect any deterioration in underlying demand. In short, the 2025 decline was supply-driven, not demand-driven: distributors continued to want Stemtech(STEK) products, but the Company was temporarily unable to supply them. With dedicated inventory funding now secured, that constraint has been addressed.

John W. Meyer, President and Chief Operating Officer of Stemtech(STEK), stated, "The sporadic unavailability of our core stem cell nutrition ingredients created challenges for our Independent Business Partners (IBPs)and customers. Despite this, the strength and commitment of our distributor network remained evident, and demand for our products has continued to grow."

Stemtech (STEK) moved quickly to strengthen its supply chain and capital position.

Most notably, the Company recently secured dedicated inventory funding, enabling:

Improved production planning

More consistent product availability

Enhanced ability to fulfill distributor and customer demand to their satisfaction.

This initiative represents a critical inflection point, positioning Stemtech(STEK) to convert growing demand into revenue while supporting the continued expansion of its global network of Independent Business Partners (IBPs).

Recent Strategic and Operational Milestones

1) Financial Performance - For the year ended December 31, 2025, the Company reduced total operating expenses by $2.3 million, or 37.7%, reflecting disciplined cost management. Stemtech(STEK) reported a net loss of $3.3 million, or $0.03 per share. Full financial results were detailed in the Company's Form 10-K filing.

-Stemtech(STEK) manages operations across three core geographic segments: North America, Latin America, and the emerging markets of Asia and India. During 2025, the Company significantly expanded agreements for its global reach, including:

Entry into China, a market of approximately 1.4 billion people, with planned local manufacturing

Entry into India, a market of approximately 1.4 billion people, with planned local manufacturing

Expansion in Taiwan through an exclusive distribution licensing agreement

Continued operations across the United States, Canada, Mexico and Ecuador

These initiatives broaden Stemtech's(STEK) access to high-growth international wellness markets and strengthen its long-term global positioning.

2) Appointment of Srilakshmi Vadlapatla as Chief Financial Officer, strengthening the Company's financial leadership and reporting capabilities

3) Expanded Life Sciences Advisory Board in addition to Dr. Enrique Martinez, MD - Stemtech(STEK) strengthened its scientific and leadership capabilities with a key appointment:

Dr. M. Zahooruddin, M.D. (Pakistan), who has recommended Stemtech(STEK) products to his patients for sixteen years with positive results, joined the Life Sciences Advisory Board

These additions enhance the Company's scientific credibility and support continued product innovation.

New Market Channels and Category Expansion - Stemtech(STEK) has expanded into new high-growth categories and distribution channels, including:

StemPets™ (launched June 2025) - A nutritional supplement for dogs and cats, entering the global pet wellness market, estimated at over $300 billion annually

BioSciences (stemtechbiosciences.com) E-commerce Platform - A new direct-to-consumer channel delivering Stemtech's(STEK) stemceutical™ products via a streamlined Shopify-based platform

Amazon distribution

These initiatives diversify revenue streams and expand customer access, creating new sales opportunities.

Product Innovation and Commercial Execution - Stemtech(STEK) continues to advance its position as The Stem Cell Nutrition Company, developing science-based regenerative wellness products designed to support natural healthy stem cell physiology.

The Company's core product portfolio includes:

RCM System

stemrelease3™ (stem cell release)

StemFlo® Advanced (stem cell circulation)

MigraStem® (stem cell migration)

OraStem® all-natural toothpaste

Cellect One® Rapid Renew Stem Cell Peptide Night Cream

StemBolix™ (Metabolic System support, currently available in Mexico only)

In 2025, Stemtech(STEK) expanded its product offerings with:

Cellect One® Shield HOCL (hypochlorous acid-based skincare)

StemPets™

These products are designed to support the release, circulation and migration of adult stem cells-supporting the body's natural regenerative processes.

A Differentiated Model Built for Scale

Stemtech (STEK) operates a capital-efficient global distribution model powered by a network of independent distributors(IBP`s) and digital commerce platforms.

This model enables:

Rapid market entry

Scalable revenue growth

Direct engagement with end consumers

We believe our Independent Business Partners represent a significant competitive advantage-bringing entrepreneurial energy, personal experience, local market knowledge and strong customer relationships to our platform.

Positioned for a Growing Market

The global wellness market continues to expand rapidly, driven by increasing demand for:

Preventative health solutions

Natural and plant-based products

Longevity and performance optimization

Within this landscape, Stemtech(STEK) occupies a differentiated position focused specifically on stem cell nutrition, a category we believe remains underpenetrated and poised for long-term growth.

Looking Ahead

As we move through 2026, our priorities are clear:

Restore consistent product availability for our customers

Convert demand into sustained revenue growth and profitability

Expand global distribution through Joint Ventures that reduce capital constraints

Advance and update product innovation

Strengthen our financial foundation

We believe the steps taken over the past year, particularly our inventory funding initiative and global expansion efforts, position Stemtech(STEK) to enter a new phase of execution.

"We are building a scalable platform in stem cell nutrition," said Charles S. Arnold. "The work we have done positions Stemtech(STEK) to better serve our distributors, meet growing demand and capitalize on the long-term opportunity in global wellness. The most meaningful validation comes from the consumers who use our products and the positive response we continue to receive from them."

On behalf of our dedicated leadership team, we thank our shareholders, partners and valued Independent Business Partners and customers for their continued support.

Sincerely,

Charles S. Arnold
Chairman and Chief Executive Officer

John W. Meyer
President and Chief Operating Officer

ABOUT STEMTECH(STEK)

Stemtech Corporation (STEK) is a publicly traded wellness company specializing in stemceuticals™ - all-natural, plant-based nutritional solutions designed to support the body's natural regenerative processes. Founded in 2018, following the acquisition of the operations from Stemtech International, Inc., (established in 2005), the company has a long history of innovation in stem cell nutrition and wellness science.

From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, Stemtech(STEK) underwent an extensive executive reorganization, and continued operations under new leadership as Stemtech Corporation(STEK). In August 2021, Stemtech(STEK) became a publicly traded company (STEK) and has expanded business opportunities for its Independent Business Partners (IBPs), who may earn incomes by sharing Stemtech(STEK) products. As THE Pioneer in stem cell nutrition-spanning nutritional, oral care, skin care and, more recently, pet health products-Stemtech(STEK) is well positioned to grow within the global wellness industry.

Stemtech's (STEK) comprehensive product portfolio reflects its dedication to optimal health. Our all-natural innovations like stemrelease3™ (supports the body's natural regenerative signaling pathways), StemFlo® Advanced (supports circulation and normal cellular communication and tissue support processes), MigraStem® (supporting healthy aging and long-term vitality), and OraStem® Toothpaste (whitening teeth, freshening breath, anti-microbial, promoting good gum health) demonstrate the company's unwavering commitment to quality-of-life products and natural effectiveness. The recent launch of Cellect One® Shield: HOCL-a multipurpose mist for skin care, cleaning, and disinfecting-and its integration with the Cellect One® Rapid Renew Stem Cell Peptide Night Cream (featuring the patented QXP ingredient) underscore Stemtech's(STEK) innovative edge in the beauty, health and wellness industry.

Stemtech (STEK) introduced StemPets™ in June 2025 - a nutritional supplement designed for both dogs and cats. Tapping into the booming global pet wellness market, valued at over $300 billion annually, Stemtech(STEK) is poised to transform pet health, with early adopters reporting remarkable improvements in health, energy, mood, and skin and hair quality for their four-legged furry family members.

For 20 years, Stemtech(STEK) has not only championed the benefits of natural, plant-based ingredients but has also led the way in scientific innovation within the wellness, anti-aging and longevity sectors. As industry forecasts and studies from reputable sources like the Global Wellness Institute project unprecedented growth, Stemtech's(STEK) unwavering commitment to quality and innovation ensures that they will remain at the forefront of this transformative journey-making everyone healthier, while slowing down the aging process naturally.

FORWARD LOOKING STATEMENTS

This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, those identified by words such as "believes," "will," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in these forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, the results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the impact of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, and other risks discussed from time to time in our filings with the Securities and Exchange Commission. We undertake no obligation to update any forward-looking statements, or any information contained in this press release or in other public disclosures, at any time. Finally, the investing public is reminded that only announcements or information about Stemtech Corporation(STEK) disseminated by the Company and bearing its name are considered official.

For Investor Relations Information Contact:
CEO Charles S. Arnold
Email: callcharlesarnold@gmail.com
Phone: +1 336-918-0507

Stemtech Corporation (STEK)
Phone: +1 954-715-6000 ext 1040
Email: invrel@stemtech.com

SOURCE: Stemtech Corporation (STEK)



View the original press release on ACCESS Newswire

Amazing this is still 1x 2, i expect no bid next week

$STEK all we need is to get to 0003 ?

$STEK time for a run up here ?
stock is cheap yet ?

$STEK LETS GO HERE TIME FOR A RUN UP
SHARES ARE CHEAP ENOUGH ?

hard to say
$FINRA has been giving out r/s like candy to all the share selling scam CEOs in the last 14 months ?

These guys R/S’d in 2021. Any concerns with that possibility again 5 years on? 

$STEK
LOTS OF CHEAPIES TO BUY ?

$STEK YES I THINK SO
and the shares are cheap

Melania trump promoted stek ceo's stock decades ago. For better or worse here?

This could go to a penny in minutes

hey good to see you here
I adding some cheap shares
looking for a good payday here
good luck...............

STEK - Hello my friend,. I have been adding at these levels! Lets get lucky!

$STEK

$STEK TIME TO LOAD SOME CHEAPIES

$STEK STEADY BUYING AT 0003 ??

$STEK SHARES CHEAP YET
LETS GO CEO
GET THIS STOCK MOVING UP ALREADY$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

$STEK isn't gonna run up by itself
time to buy some real cheap shares ????????

$STEK SHARES ARE CHEAP YET
IT SHOULD RUN UP HARD
TIME TO BUY SOME CHEAPIES ?

$STEK all we need is some good volume to get past the 0002s........0003
AND THE FIRE WORKS START ?

25,000,000 buy in

Action 😂 

$STEK READY TO ROLL UP AND OUT OF THE TRIPS $$$$$$$$$$$$$$$$$$$$$$
and still the share price is so cheap
dont miss it for a few dollars ??

$STEK BUY SOME 0003 THEN
ITS STILL DIRT CHEAP

$STEK >>>>>>>>>>>>>>GOING THE WRONG WAY
SHARES ARE CHEAP YET FOR A REVERSAL ?

$STEK time to load up on these cheapies

Finished filling me up after 2 weeks today to

Filled me 5mill 2's here today!

$STEK LETS GO HERE TIME FOR THIS TO RUN UP

Stemtech Secures Inventory Funding
ACCESS NEWSWIRE 6:30 AM ET 4/7/2026
Symbol Last Price Change
STEK 0.00015down +5E-05 (+50%)
QUOTES AS OF 01:53:07 PM ET 04/07/2026
NAPLES, FL / ACCESS Newswire / April 7, 2026 / Stemtech Corporation (STEK) , the global leader and pioneer in stem cell nutrition, secures funding for production of $2.5 Million of Inventory to protect against supply chain interruptions.

(Stemtech Corporation(STEK) - OTCID:STEK)
"Live Longer - Live Better - Live Younger"

Stemtech (STEK) announces that we have successfully secured funding to acquire raw materials and components for production of $2.5 million of inventory. This strategic investment, already in hand with purchase orders issued for the first million, is essential for maintaining a steady and sufficient stock of our premium-stem cell nutrition and regenerative science products, which have been integral to our company's mission for over twenty years.

Charles S. Arnold, Stemtech's(STEK) Chairman and CEO, states "we have received substantial funding to expand inventory production. Our 20 years of experience affirm the vital role our products play in natural human supplementation, particularly in areas related to anti-aging and longevity. These products have proven themselves essential tools for individuals seeking to enhance their health naturally while providing anti-aging effectively. As a company, Stemtech(STEK) is deeply committed to health and wellness, and we recognize the critical importance of product availability. Over the past year, increased demand for our key core products - including the RCM system with its SR3 stem cell Release, the StemFlo Advanced Circulation product, and MigraStem for stem cell Migration - has occasionally resulted in out-of-stock situations. These interruptions of product availability have been disappointing, not only for our customers but also for our dedicated Stemtech(STEK) company team, who understand the benefits our products provide in supporting the body's natural regenerative processes".

President and COO, John W. Meyer, says "we want to emphasize the significance of this investment. Having sufficient inventory on hand means that Stemtech(STEK) can now provide an uninterrupted supply to meet the fast-growing demand for not only our network marketing business (www.stemtech.com) to support our Independent Business Partners (IBPs), but also our growing retail operations. This development enables our customers and partners to have greater confidence in consistently accessing the products they trust and rely upon. We take great pride in our ability to support the health and wellness journeys of so many people worldwide".

Moreover, Alejandro Carrillo, Vice President of Global Operations, has emphasized the operational advantages this funding provides. "With a strong inventory foundation, we are better positioned to successfully expand our reach through retail channels and online platforms, including our recently launched www.StemtechBiosciences.com e-commerce offering. Ensuring product availability across all our markets and beyond is vital as we continue our planned expansion efforts".

Stemtech (STEK) recognizes the importance of strategic investments like this one, which safeguard our company's ability to deliver excellence while advancing as the pioneer and leader in regenerative science and nutrition. Today, when you ask AI who stands out as the Number 1 stem cell nutrition company, you will see Stemtech(STEK) as THELEADER - Extraordinary Stemtech(STEK).


In 2024, the stem cell industry was $4.6 billion dollars and the estimates are that by 2030, the market will surpass $30 billion dollars.

ABOUT STEMTECH(STEK)
Stemtech Corporation (STEK) is a publicly traded wellness company specializing in stemceuticals™ - all-natural, plant-based nutritional solutions designed to support the body's natural regenerative processes. Founded in 2018, following the acquisition of the operations from Stemtech International, Inc., (established in 2005), the company has a long history of innovation in stem cell nutrition and wellness science.

From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, Stemtech(STEK) underwent an extensive executive reorganization, and continued operations under new leadership as Stemtech Corporation(STEK). In August 2021, Stemtech(STEK) became a publicly traded company (STEK) and has expanded business opportunities for its Independent Business Partners (IBPs), who may earn incomes by sharing Stemtech(STEK) products. Stemtech(STEK) is well positioned as the pioneer in stem cell nutrition, oral, skin care and soon pet health products, to increase sales in the wellness industry.

Stemtech's (STEK) comprehensive product portfolio reflects its dedication to optimal health. Our all-natural innovations like stemrelease3™ (supports the body's natural regenerative signaling pathways), StemFlo® Advanced (supports circulation and normal cellular communication and tissue support processes), MigraStem® (supporting healthy aging and long-term vitality), and OraStem® Toothpaste (whitening teeth, freshening breath, anti-microbial, promoting good gum health) demonstrate the company's unwavering commitment to quality-of-life products and natural effectiveness. The recent launch of Cellect One® Shield: HOCL-a multipurpose mist for skin care, cleaning, and disinfecting-and its integration with the Cellect One® Rapid Renew Stem Cell Peptide Night Cream (featuring the patented QXP ingredient) underscore Stemtech's(STEK) innovative edge in the beauty, health and wellness industry.

Stemtech (STEK) introduced StemPets™ in June 2025 - a nutritional supplement designed for both dogs and cats. Tapping into the booming global pet wellness market, currently valued at over $303 billion annually, Stemtech(STEK) is poised to transform pet health, with early adopters reporting remarkable improvements in health, energy, mood, and skin and hair quality for their four-legged furry family members.

For 20 years, Stemtech(STEK) has not only championed the benefits of natural, plant-based ingredients but has also led the way in scientific innovation within the wellness, anti-aging and longevity sectors. As industry forecasts and studies from reputable sources like the Global Wellness Institute project unprecedented growth, Stemtech's(STEK) unwavering commitment to quality and innovation ensures that they will remain at the forefront of this transformative journey-making everyone healthier, while slowing down the aging process naturally.

FORWARD LOOKING STATEMENTS
This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, those identified by words such as "believes," "will," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in these forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, the results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the impact of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, and other risks discussed from time to time in our filings with the Securities and Exchange Commission. We undertake no obligation to update any forward-looking statements, or any information contained in this press release or in other public disclosures, at any time. Finally, the investing public is reminded that only announcements or information about Stemtech Corporation(STEK) disseminated by the Company and bearing its name are considered official.

For Investor Relations Information Contact:
CEO Charles S. Arnold
Email: callcharlesarnold@gmail.com
Phone: +1 336-918-0507

Stemtech Corporation (STEK)
Phone: +1 954-715-6000 ext 1040
Email: invrel@stemtech.com

SOURCE: Stemtech Corporation (STEK)



View the original press release on ACCESS Newswire


Copyright 2026 ACCESS Newswire. All Rights Reserved.

Took some 2's here today!

News!!! Stemtech secures inventory funding.

junk want to go up so thay can dilute more

Corporate dUmPDATE

nobody is coming to save this junk they dumping 0.0001s fraud operations

not so much today. but 911 trades 2 of them already. mms want it at .0001 imo

Huge Slaps!!!